{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:30:07Z","timestamp":1793464207545,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40271-026-00829-y","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:17:40Z","timestamp":1782753460000},"page":"845-856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Experiences of People with Type 2 Diabetes and Healthcare Professionals with Once-Weekly Insulin Efsitora Alfa in QWINT Phase 3 Trials: Qualitative In-Trial Interviews"],"prefix":"10.1007","volume":"19","author":[{"given":"William H.","family":"Polonsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4701-8825","authenticated-orcid":false,"given":"Carla","family":"Dias-Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Ilag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia Firmino","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Threlkeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Child","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia T.","family":"Gelsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"10085","key":"829_CR1","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","volume":"389","author":"S Chatterjee","year":"2017","unstructured":"Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239\u201351.","journal-title":"Lancet"},{"issue":"3","key":"829_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3122\/jabfm.2019.03.180162","volume":"32","author":"L Perreault","year":"2019","unstructured":"Perreault L, et al. Initiation and titration of basal insulin in primary care: barriers and practical solutions. J Am Board Fam Med. 2019;32(3):431\u201347.","journal-title":"J Am Board Fam Med"},{"key":"829_CR3","doi-asserted-by":"crossref","unstructured":"Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786.","DOI":"10.2337\/dci22-0034"},{"key":"829_CR4","doi-asserted-by":"crossref","unstructured":"Committee ADAPP, 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142025. Diabetes Care. 2025;48(Supplement_1):S181\u2013S206.","DOI":"10.2337\/dc25-S009"},{"issue":"3","key":"829_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/dom.13132","volume":"20","author":"D Russell-Jones","year":"2018","unstructured":"Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metabol. 2018;20(3):488\u201396.","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"829_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/pdi.1574","volume":"28","author":"A Gherman","year":"2011","unstructured":"Gherman A, et al. Psychological insulin resistance: a critical review of the literature. Pract Diabetes Int. 2011;28(3):125\u2013128d.","journal-title":"Pract Diabetes Int"},{"key":"829_CR7","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2147\/PPA.S106821","volume":"10","author":"WH Polonsky","year":"2016","unstructured":"Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adher. 2016;10:1299\u2013307.","journal-title":"Patient Prefer Adher"},{"issue":"1","key":"829_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2337\/diaclin.25.1.36","volume":"25","author":"MM Funnell","year":"2007","unstructured":"Funnell MM. Overcoming barriers to the initiation of insulin therapy. Clin Diabetes. 2007;25(1):36\u20138.","journal-title":"Clin Diabetes"},{"issue":"11","key":"829_CR9","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1007\/s13300-024-01652-0","volume":"15","author":"FT Gelsey","year":"2024","unstructured":"Gelsey FT, et al. Perspectives and preferences of people with type 2 diabetes for the attributes of weekly insulin. Diabetes Ther. 2024;15(11):2367\u201379.","journal-title":"Diabetes Ther"},{"issue":"3","key":"829_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1124\/jpet.122.001105","volume":"382","author":"JS Moyers","year":"2022","unstructured":"Moyers JS, et al. Preclinical characterization of LY3209590, a novel weekly basal insulin fc-fusion protein. J Pharmacol Exp Ther. 2022;382(3):346\u201355.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"829_CR11","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1111\/dom.15604","volume":"26","author":"RM Bergenstal","year":"2024","unstructured":"Bergenstal RM, et al. Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme. Diabetes Obes Metab. 2024;26(8):3020\u201330.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"829_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2502796","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, et al. Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy. N Engl J Med. 2025;393(4):325\u201335.","journal-title":"N Engl J Med"},{"issue":"23","key":"829_CR13","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa2403953","volume":"391","author":"C Wysham","year":"2024","unstructured":"Wysham C, et al. Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment. N Engl J Med. 2024;391(23):2201\u201311.","journal-title":"N Engl J Med"},{"issue":"10497","key":"829_CR14","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/S0140-6736(25)01044-X","volume":"405","author":"A Philis-Tsimikas","year":"2025","unstructured":"Philis-Tsimikas A, et al. Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial. Lancet. 2025;405(10497):2279\u201389.","journal-title":"Lancet"},{"issue":"10497","key":"829_CR15","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1016\/S0140-6736(25)01069-4","volume":"405","author":"T Blevins","year":"2025","unstructured":"Blevins T, et al. Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. Lancet. 2025;405(10497):2290\u2013301.","journal-title":"Lancet"},{"key":"829_CR16","doi-asserted-by":"crossref","unstructured":"Miller E, et al. Evaluation of overall health state, treatment burden, and satisfaction with insulin efsitora alfa (efsitora) vs. daily comparator in adults with type 2 diabetes in the QWINT Clinical Trial Program. Diabetes Ther. 2026;17(3):431\u2013447.","DOI":"10.1007\/s13300-025-01833-5"},{"key":"829_CR17","unstructured":"Food and Drug Administration, Patient-focused drug development: collecting comprehensive and representative input. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. 2020 [cited 2024 June 06]; https:\/\/www.fda.gov\/media\/139088\/download."},{"key":"829_CR18","doi-asserted-by":"crossref","unstructured":"Elo S, Kyng\u00e4s H. The qualitative content analysis process. J Adv Nurs. 2008;62(1):107\u2013115.","DOI":"10.1111\/j.1365-2648.2007.04569.x"},{"issue":"5","key":"829_CR19","doi-asserted-by":"publisher","first-page":"e0232076","DOI":"10.1371\/journal.pone.0232076","volume":"15","author":"G Guest","year":"2020","unstructured":"Guest G, Namey E, Chen M. A simple method to assess and report thematic saturation in qualitative research. PLoS ONE. 2020;15(5):e0232076.","journal-title":"PLoS ONE"},{"issue":"8","key":"829_CR20","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2013eliciting concepts for a new PRO instrument. Val Health. 2011;14(8):967\u201377.","journal-title":"Val Health"},{"issue":"7","key":"829_CR21","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.2337\/dc18-0116","volume":"41","author":"KM Pantalone","year":"2018","unstructured":"Pantalone KM, et al. Clinical inertia in type 2 diabetes management: evidence from a large, real-world data set. Diabetes Care. 2018;41(7):e113\u20134.","journal-title":"Diabetes Care"},{"key":"829_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/DMSO.S99732","volume":"9","author":"Q Qiao","year":"2016","unstructured":"Qiao Q, et al. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany. Diabetes Metab Syndr Obes. 2016;9:201\u20135.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"829_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s13300-021-01189-6","volume":"13","author":"WH Polonsky","year":"2022","unstructured":"Polonsky WH, et al. Higher rates of persistence and adherence in patients with type 2 diabetes initiating once-weekly vs daily injectable glucagon-like peptide-1 receptor agonists in US Clinical Practice (STAY Study). Diabetes Ther. 2022;13(1):175\u201387.","journal-title":"Diabetes Ther"},{"issue":"4","key":"829_CR24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/dom.13603","volume":"21","author":"R Mody","year":"2019","unstructured":"Mody R, et al. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States. Diabetes Obes Metab. 2019;21(4):920\u20139.","journal-title":"Diabetes Obes Metab"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00829-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-026-00829-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00829-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:37:53Z","timestamp":1793461073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-026-00829-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["829"],"URL":"https:\/\/doi.org\/10.1007\/s40271-026-00829-y","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"WHP has served as a consultant for Sanofi, Eli Lilly, Dexcom, Abbott Diabetes Care, Mannkind, and Vertex, and receives research support from Dexcom, Abbott Diabetes, and Eli Lilly. ELL, CD-B, AC, and KB are employees of PPD Evidera Patient Centered Research, Thermo Fisher Scientific, which received financial support from Eli Lilly for work on this study.\u00a0LI, LFG, RT, CJC, MBD, EM, and FTG are employees and stockholders of Eli Lilly, which funded this study.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":2,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board (IRB) approvals were obtained for protocol addenda to incorporate PwD and HCP interviews for each of the three clinical trials (IRB number: 1368158) in the US, Canada, and Mexico.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent to participate was obtained prior to participation in the in-trial interview sub-study.","order":5,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We comply with the authorship standards of the International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (\n                      \n                      ) for all publications, including abstracts and presentations. Individual contributions are as follows: WHP: Writing \u2013 review and editing. ELL: Conceptualization; methodology; writing \u2013 review and editing; supervision; project administration. CD-B: Conceptualization; methodology; validation; formal analysis; investigation; resources; data curation; writing \u2013 original draft; writing \u2013 review and editing; visualization; supervision; project administration. AC: Conceptualization; methodology; validation; formal analysis; investigation; resources; data curation; writing \u2013 original draft; writing \u2013 review and editing; visualization; supervision; project administration. KB: Formal analysis; writing \u2013 review and editing. LI: Conceptualization; methodology; writing\u00a0\u2013 review and editing. LFG and RT: Conceptualization; methodology; writing \u2013 review and editing. CJC: Conceptualization; methodology; writing \u2013 review and editing. MBD: Writing \u2013 original draft; writing \u2013 review and editing; visualization. EM: Writing \u2013 review and editing. FTG: Conceptualization; methodology; writing \u2013 original draft; writing \u2013 review and editing; visualization; supervision.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}